IART
Integra LifeSciences Holdings
NASDAQ: IART · HEALTHCARE · MEDICAL DEVICES
$10.08
-6.15% today
Updated 2026-04-29
Market cap
$785.61M
P/E ratio
—
P/S ratio
0.48x
EPS (TTM)
$-6.74
Dividend yield
—
52W range
$9 – $17
Volume
0.8M
WallStSmart proprietary scores
52
out of 100
Grade: C
Hold
Investment rating
3.3
Growth
D5.3
Quality
C+3.5
Profitability
D7.7
Valuation
B+3/9
Piotroski F-Score
Weak
0.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$16.00
+58.73%
12-Month target
—
—
Intrinsic (DCF)
$95.81
Margin of safety
+88.33%
1 Strong Buy2 Buy4 Hold1 Sell2 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 88.33% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 0.76 — distress zone
- Thin margins at -31.60%
- Negative free cash flow $-37.25M
- Revenue declining -1.70% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.56B | $1.54B | $1.61B | $1.64B | $1.64B |
| Net income | $180.55M | $67.74M | $-6.94M | $-516.47M | $-1.70M |
| EPS | — | — | — | — | $-6.74 |
| Free cash flow | $217.38M | $73.09M | $24.96M | $-31.05M | $-37.25M |
| Profit margin | 11.59% | 4.39% | -0.43% | -31.58% | -31.60% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-11 | VEILLON-BERTELOOT, CHANTAL | Buy | 41,783 | — |
| 2026-03-11 | VEILLON-BERTELOOT, CHANTAL | Sale | 5,420 | $9.61 |
| 2026-03-11 | SINGH, HARVINDER | Buy | 60,865 | — |
Peer comparison
Smart narrative
Integra LifeSciences Holdings trades at $10.08. Our Smart Value Score of 52/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 0.76, it sits in the distress. TTM revenue stands at $1.64B. with profit margins at -31.60%. Our DCF model estimates intrinsic value at $95.81.
Frequently asked questions
What is Integra LifeSciences Holdings's stock price?
Integra LifeSciences Holdings (IART) trades at $10.08.
Is Integra LifeSciences Holdings overvalued?
Smart Value Score 52/100 (Grade C, Hold). DCF value $95.81.
What is the price target of Integra LifeSciences Holdings (IART)?
The analyst target price is $16.00, representing +58.7% upside from the current price of $10.08.
What is the intrinsic value of Integra LifeSciences Holdings (IART)?
Based on our DCF model, intrinsic value is $95.81, a +88.3% margin of safety versus $10.08.
What is Integra LifeSciences Holdings's revenue?
TTM revenue is $1.64B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
0.76 — distress.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.48x
ROE-39.90%
Beta1.07
50D MA$10.17
200D MA$12.43
Shares out0.08B
Float0.06B
Short ratio—
Avg volume0.8M
Performance
1 week-2.33%
1 month+7.01%
3 months-9.11%
YTD-18.84%
1 year—
3 years—
5 years—